Optimi Health Corp. OPTH
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -60.36%
- 1 year
- -60.36%
- Open
- 2.58
- Prev close
- 2.60
- Mkt cap
- 13.80M
- Vol
- 59.41K
- Avg vol
- 39.02K
- EPS
- -1.56
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.02
- High
- 2.60
News
5 days ago globenewswire.com
Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical developer and…
-
1 week ago benzinga.com
Optimi Health Completes Latest Production Batch Of Its MDMA Finished Drug Product; Proposed Phase 3 Trial Expected To Begin In 2027
The capsules were manufactured at Optimi’s GMP facility in Princeton, British Columbia, under its Health Canada Drug Establishment Licence, and are expected to supply three programs: the recently…
1 week ago globenewswire.com
Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
Batch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia Health Canada-authorized trial…
3 weeks ago globenewswire.com
Optimi Health to Present at the ThinkEquity Conference
VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or “the Company”), a commercial-stage pharmaceutical manufacturer…
1 month ago globenewswire.com
Optimi Health Appoints Melanie Pump to Board of Directors
Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies Seasoned finance executive…
1 month ago defenseworld.net
Optimi Health Corp. (NASDAQ:OPTH) Stock Short Interest Jumps 109.1%
Optimi Health Corp. (NASDAQ: OPTH - Get Free Report) was the target of a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 20,500…
-
1 month ago benzinga.com
Optimi Health Completes Production Batch Of 5mg Naturally Derived Psilocybin Capsules, Manufactured End To End At cGMP Facility In Princeton, British Columbia
Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the…
1 month ago globenewswire.com
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer…
1 month ago globenewswire.com
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer…
1 month ago benzinga.com
Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial
As Elon Musk touts psychedelics for mental health and the FDA holds hearings, Optimi Health (OPTH) supplies commercial MDMA & psilocybin.
-
1 month ago benzinga.com
Optimi Health Plans To Initiate A Phase 3 Clinical Trial Evaluating MDMA-Assisted Therapy For PTSD Authorized By Health Canada; Trial Is Expected To Begin In 2027
The Phase 3 clinical trial is intended to enroll up to 100 participants across multiple sites in Canada, with enrollment focused on veterans and current or former frontline workers, including…
1 month ago globenewswire.com
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers Health Canada-authorized trial to evaluate efficacy…
-
1 month ago benzinga.com
Optimi Health Plans To Initiate Multisite Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy For Individuals With Major Depressive Disorder In H1 2027, With Dosing Expected To Be Complete By 2027 End
Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027Up to 200 participants at sites across Canada, among…
1 month ago globenewswire.com
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027
1 month ago globenewswire.com
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated…
2 months ago globenewswire.com
Optimi Health Establishes Discretionary Equity Facility
VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of…
4 months ago prnewswire.com
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
/PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of
-
4 months ago benzinga.com
Optimi Health Exports Third Shipment Of Its 5Mg Psilocybin Product To Australia Since September 2025
The shipment included 1,000 capsules of 5mg psilocybin, which are being prescribed in Australia for treatment-resistant depression ("TRD"), an indication for which regulated patient access is…
4 months ago globenewswire.com
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi's 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in…
-
4 months ago benzinga.com
Optimi Health Completes Production Of Two Microdose Psilocybin Finished Drug Products, Formulated At 1 Mg And 2 Mg Dosages; Products Available To Authorized Clinical Research Organizations
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studiesNew microdose formats extend Optimi's…
4 months ago globenewswire.com
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's…
4 months ago prnewswire.com
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
/PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of
4 months ago globenewswire.com
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization…
4 months ago gurufocus.com
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development PR Newswire VANCOUVER, BC,
4 months ago prnewswire.com
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
/PRNewswire/ - via IBN - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer
4 months ago globenewswire.com
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat PTSD,…
5 months ago globenewswire.com
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
Optimi's 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United…
-
5 months ago benzinga.com
Optimi Health Prices Underwritten Public Offering Of 2.40M Common Shares At $6.25/Shr
Common Shares to Trade on the Nasdaq Capital Market Under the Symbol "OPTH"VANCOUVER, BC, May 20, 2026 /CNW/ - Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a…